"CAPItello-292" / D361DC00001

Topic of Study: Breast Cancer

Sponsor: AstraZeneca

Principal Investigator: David A. Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Shannon Householder, RN, 410-951-7908; Sarah Orndorff, RN 410-332-9459

Coordinated Through: Institutional Research

This is a Phase Ib/III, open-label, randomised study of Capivasertib plus CDK4/6 inhibitors and Fulvestrant versus CDK4/6 inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative locally advanced, unresectable or metastatic breast cancer. (Clinicaltrials.gov ID#: NCT04862663)